Orexin (also known as hypocretin) neurons are a population of specialized neurons located in the lateral hypothalamus that play critical roles in regulating wakefulness, arousal, appetite, and energy homeostasis[1]. These neurons are essential for maintaining normal sleep-wake cycles, and their degeneration is strongly implicated in narcolepsy. Additionally, orexin system dysfunction has been increasingly recognized in neurodegenerative diseases, particularly Parkinson's disease[2].
| Property |
Value |
| Category |
Hypothalamic Neuropeptide Neurons |
| Neuropeptides |
Orexin-A (hypocretin-1), Orexin-B (hypocretin-2) |
| Receptors |
OX1R (HCRTR1), OX2R (HCRTR2) |
| Location |
Lateral hypothalamus, Perifornical area |
| Neuron Count |
~70,000 neurons in human brain |
¶ Location and Connectivity
Orexin neurons are primarily located in:
- Lateral Hypothalamus (LH): Main population
- Perifornical Area (PeF): Dorsomedial to the fornix
- Dorsomedial Hypothalamus (DMH): Minor population
These neurons project extensively throughout the brain:
- Ascending projections: To basal forebrain, cortex, thalamus
- Descending projections: To brainstem, spinal cord
- Key targets: Locus coeruleus, dorsal raphe, tuberomammillary nucleus, ventral tegmental area
Orexin neurons exhibit unique electrophysiological characteristics:
- Spontaneous firing: Tonic activity during wakefulness
- Quiet periods: Reduced firing during sleep
- Intracellular calcium: High baseline calcium levels
- Metabolic sensing: Respond to glucose, leptin, ghrelin
Two related neuropeptides are produced:
| Peptide |
Alias |
Amino Acids |
Receptor Affinity |
| Orexin-A |
Hypocretin-1 |
33 AA |
OX1R > OX2R |
| Orexin-B |
Hypocretin-2 |
28 AA |
OX2R only |
- OX1R (HCRTR1): Prefers orexin-A; expressed in locus coeruleus, amygdala
- OX2R (HCRTR2): Binds both orexin-A and orexin-B; expressed in hypothalamus, cortex
¶ Wakefulness and Arousal
Orexin neurons are the central driver of arousal:
- Stabilize wakefulness: Prevent transitions to sleep
- Activate monoaminergic systems: Stimulate norepinephrine, serotonin, acetylcholine
- Enhance cortical activation: Promote desynchronized EEG
- Circadian regulation: Integrate circadian and homeostatic sleep signals
Orexin neurons integrate metabolic signals:
- Glucose sensing: Respond to changes in extracellular glucose
- Leptin signaling: Receive input from leptin (satiety hormone)
- Ghrelin signaling: Respond to ghrelin (hunger hormone)
- Energy expenditure: Increase motor activity and thermogenesis
Orexin promotes food-seeking behavior:
- Increase appetite: Direct orexigenic effect
- Food motivation: Enhance reward-driven feeding
- Energy balance: Coordinate feeding with energy expenditure
Narcolepsy type 1 (with cataplexy) is characterized by:
- Orexin neuron loss: ~90% loss of orexin neurons
- CSF orexin-A: Undetectable or very low (<110 pg/mL)
- Autoimmune hypothesis: T-cell mediated destruction
- HLA association: DQB1*06:02 susceptibility
Emerging evidence links orexin dysfunction to PD:
- Orexin neuron loss: Reduced orexin neurons in PD brains
- Sleep fragmentation: Common in PD, orexin may contribute
- Cognitive decline: Low orexin-A correlates with dementia in PD
- REM sleep behavior disorder: Often precedes PD, orexin involvement
In AD, orexin system changes include:
- Elevated orexin-A: CSF levels increased in AD
- Sleep disruption: Common in AD, orexin may contribute
- Amyloid interaction: Orexin may affect Aβ metabolism
- Obesity: Reduced orexin signaling may contribute
- Depression: Altered orexin function in some patients
- Addiction: Orexin in reward and reinforcement
Current and emerging therapies:
- Orexin receptor agonists: Small molecule orexin mimetics
- Histamine H3 antagonists: Promote wakefulness indirectly
- Sodium oxybate: For cataplexy and sleep paralysis
Potential therapeutic approaches:
- Orexin receptor modulators: For PD sleep disorders
- Orexin-A administration: Potential neuroprotective effects
- Combination therapies: Target orexin + other systems
- Orexin/ataxin-3 mice: Progressive orexin neuron loss
- Orexin knockout mice: Narcolepsy-like phenotype
- Orexin receptor knockout mice: Sleep-wake abnormalities
- Orexin-A/B antagonists: SB-9200, Suvorexant
- Orexin receptor agonists: For wake promotion
-
[1] Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010;68(6):1023-1042.
-
[2] Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain. 2007;130(Pt 6):1577-1585.
-
[3] Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39-40.
-
[4] Tsujino N, Sakurai T. Role of orexin in modulating arousal, wakefulness and sleep. Front Neurol Neurosci. 2021;45:52-63.
-
[5] Borgland SL, Taha SA, Sarti F, Fields HL, Berridge CW. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49(4):589-601.
-
[6] Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.